[First IVF Dynamic Report] Guannian Partners with First IVF Hong Kong to Chart a New Blueprint for Assisted Reproduction

On February 6, 2025, Guannian—the premium brand under Beijing Changsheng Kuangshi Technology Co., Ltd.—officially announced a deep strategic partnership with First IVF Center (Hong Kong) Limited, a subsidiary of U.S.-listed NEWGENIVF Group Limited (NIVF). This powerful alliance is set to ignite a new wave of industry advancement and jointly usher in a groundbreaking era for assisted reproduction.

On February 6, 2025, Guannian—the premium brand under Beijing Changsheng Kuangshi Technology Co., Ltd.—officially announced a deep strategic partnership with First IVF Center (Hong Kong) Limited, a subsidiary of U.S.-listed NEWGENIVF Group Limited (hereinafter referred to as "First IVF"). This powerful alliance is akin to dropping a重磅 bomb in the field of assisted reproduction, certain to spark a new wave of industry development and jointly inaugurate a pioneering chapter in assisted reproduction.

Guannian, a vanguard premium brand in China’s anti-aging technology sector, has been entrusted since its inception with the mission of exploring life’s mysteries and deeply integrating science and technology with human health. Leveraging profound scientific research foundations, Guannian operates like a master craftsman—meticulously blending world-class life sciences technologies with the unique physiological characteristics of Asian populations. With precision focus, Guannian customizes personalized tech-driven anti-aging and longevity solutions for Chinese individuals’ health needs—a distinctive approach that sets it apart and garners widespread attention in the industry.

Dr. Lin Xiongbin, Chief Scientist of the company, serves as the visionary navigator on Guannian’s R&D journey. Through dedicated research and an unwavering passion for science, he pioneered autologous stem cell technology—a shining star within the industry. Notably, this technology has achieved breakthrough progress in male and female autologous reproductive stem cells. For individuals struggling with infertility, premature ovarian insufficiency, or age-related decline in reproductive function, this innovation shines like a beacon of hope—illuminating their path toward fulfilling their dreams of parenthood and demonstrating immense clinical potential.

First IVF, a key subsidiary of U.S.-listed NEWGENIVF Group Limited (Nasdaq: NIVF), was founded in Hong Kong in 2010 and has rapidly emerged as a leading pan-Asian life science medical group specializing in fertility care. Widely recognized as a professional fertility assistance provider, First IVF delivers high-quality assisted reproduction services to clients across mainland China, Hong Kong, Macau, Taiwan, and Southeast Asia—acting as a trusted guardian throughout their fertility journeys.

First IVF’s international footprint is both extensive and deeply rooted: its clinics operate in Thailand, Cambodia, and Kyrgyzstan, offering comprehensive services within appropriate legal jurisdictions. Simultaneously, it maintains carefully curated service hubs across the United States, Japan, Hong Kong (China), and Singapore—forming a broad, efficient, and empathetic service network that delivers convenient, premium healthcare experiences to clients across the Asia-Pacific region. Notably, in April 2024, the group successfully listed on the Nasdaq Stock Market—a milestone underscoring its robust capabilities and expansive growth prospects, much like an eagle soaring confidently across the skies of assisted reproduction.

This collaboration between Guannian and First IVF represents a seamless fusion of cutting-edge technology and complementary resources. Both parties will comprehensively integrate their respective technical expertise and market advantages to uncover latent opportunities within the assisted reproduction landscape. Guannian’s advanced autologous stem cell technology will serve as a vital bridge—seamlessly connecting First IVF’s world-class technical infrastructure and vast global service network. Together, they will co-develop forward-looking, reliable fertility support solutions tailored specifically for China’s high-end clientele—helping them realize their dreams of parenthood and bringing the joy of new life to countless families.

"We are deeply honored to embark on this profoundly meaningful collaboration with First IVF Group. As a U.S.-listed, Asia-renowned assisted reproduction service provider, First IVF’s strong endorsement of the Guannian brand further fuels our momentum," said Mr. Wei Zhigang, Founder of Guannian, with palpable enthusiasm. "Through this deep partnership, Guannian’s frontier technologies and exceptional service standards will precisely reach more Chinese families in need—while also contributing meaningfully to the iterative advancement of fertility science and technology."

Ms. Luo Hong, CEO of First IVF Group’s Greater China Region, likewise expressed passionate optimism about the collaboration: "Guannian’s achievements in autologous stem cell technology are widely acknowledged as industry-leading. We firmly believe that our close cooperation will inject fresh vitality into the fertility support market—and help more Chinese families welcome the arrival of new life."

This partnership with First IVF Group marks Guannian’s inaugural step into international markets. It is reported that Guannian will actively expand into Southeast Asian markets—embarking on a bold new expedition, like a courageous explorer, to deliver advanced technologies and premium services to more countries and regions.

About Beijing Changsheng Kuangshi Technology Co., Ltd.

Beijing Changsheng Kuangshi Technology Co., Ltd. is an innovative pioneer deeply engaged in the anti-aging technology sector. Under its dynamic brand “Guannian,” the company provides customized aging-intervention and longevity health management services. Guided consistently by the principles of innovation, professionalism, and empathy, the company relentlessly explores the frontiers of life sciences—contributing meaningfully to human health and longevity.

About First IVF Group Hong Kong

First IVF Group Hong Kong is a leading pan-Asian life science medical group, dedicated since 2010 to delivering professional, comprehensive assisted reproduction services—including state-of-the-art in vitro fertilization (IVF) treatments. Grounded in globally sourced, high-quality medical resources, the Group acts as a steadfast dream-builder—empowering diverse families to achieve their fertility aspirations and welcoming the joyful laughter of newborns into countless homes.

This article is a public-information summary published by WFA. It is intended for industry, media and the general public, and does not constitute medical or investment advice.